Breaking News

AbbVie to Acquire Aliada Therapeutics for $1.4B

Aliada's lead compound is an anti-pyroglutamate amyloid beta antibody, a potential best-in-class therapy for Alzheimer's disease.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AbbVie entered a definitive agreement to acquire Aliada, a biotechnology company developing therapies using a novel blood-brain barrier (BBB)-crossing technology for central nervous system (CNS) diseases, for $1.4 billion in cash. This transaction is expected to close in 4Q24, subject to regulatory approvals and other customary closing conditions.    Aliada’s lead investigational asset utilizing its delivery technology, ALIA-1758, is an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody i...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters